ArticleFrontiers in oncology2026
Refractory thrombocytopenia induced by enzalutamide combined with docetaxel chemotherapy in a metastatic castration-resistant prostate cancer patient with bone marrow metastasis: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Enzalutamide combined with docetaxel is one of the effective therapeutic regimens for metastatic castration-resistant prostate cancer (mCRPC), which significantly prolongs progression-free survival (PFS). For mCRPC patients with bone marrow metastasis (BMM), bone marrow metastasis itself impairs the bone marrow microenvironment and results in reduced hematopoietic function. The combined therapy may induce life-threatening refractory thrombocytopenia, which has been rarely reported in clinical practice. Case presentation: A 62-year-old male patient with mCRPC and confirmed bone marrow metastasis was reported herein. After progression to mCRPC, the patient was treated with enzalutamide plus docetaxel, followed by grade 4 refractory thrombocytopenia. The lowest platelet count decreased to 3×10 Conclusion: Enzalutamide combined with docetaxel may increase the risk of refractory grade 4 thrombocytopenia among mCRPC patients with bone marrow infiltration, as illustrated by this single clinical case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.